|
|
"Billy Foundation"
Recommended Articles
from Cancer.Net Features
Cancer.Net Features are weekly articles that provide practical, timely
information
for people with cancer and their families and friends.
Clinical
Trials
The
"Billy Foundation" is pleased to partner with the
following companies to bring to you the latest clinical trials
to aid in the education and fight against melanoma.
Current clinical trials are shown below.
Click here for the Billy Foundation Clinical Trial Match
Service!
Study to
compare investigational compound with existing therapies for
advanced melanoma
Clinical trial currently enrolling patients
A research study is underway
at 45 sites in the United States and up to 60 sites globally
to compare how long patients with advanced melanoma live
when they get the investigational compound to how long
patients live when they get either dacarbazine or
temozolomide, two of the available drug treatment options.
This Phase III study, known as A3671009, is seeking adults
(18 years of age and older) with surgically incurable Stage
IIIC or
IV melanoma
who have received no prior chemotherapy, immunotherapy, or
biologic therapy for the treatment of metastatic melanoma.
The investigational
compound, ticilimubab, is a fully human monoclonal antibody.
It is being studied to determine if it can stimulate
patients’ immune systems to attack their tumors.
For more information or to
determine your eligibility for participation in the study,
go to www.pfizeroncology.com to complete a patient
profile and talk to a study representative, or call
1-877-369-9753.
You
can use this site to find a wealth of information about clinical
research, including listings of more than 41,000 active industry
and government-sponsored clinical trials, as well as new drug
therapies in research and those recently approved by the FDA.
Our site is designed to be an open resource for patients
interested in participating in clinical trials and for research
professionals.
Proleukin (IL-2) is FDA
approved for the treatment of Metastatic Melanoma.
For a partial list of physicians and institutions
experienced in the administration of Proleukin therapy,
please visit
www.proleukin.com/referral
Clinical
Trials at the Arizona Cancer Center
Provided
courtesy of Dr.
Evan Hersh
1. Canvaxin as adjuvant therapy for Stage III and IV
melanoma
2. Short term high dose adjuvant Interferon alpha
for Stage II and III melana
3. Protocols for Stage IV melanoma
b. DTIC with or without genasense
c. MDX0-010 (anti-CTLA-4 Ig) with or without DTIC
d. allovectin 7 intratumoral gene therapy
f. ABI 007 (taxol in an albumin nano particle) Phase I,
Phase II pending
g. ILX 651 Phase I (dolostatin analogue) Phase I, Phase
II pending |
Clinical
Trials at The Angeles Clinic and Research Institute
Provided
courtesy of Dr.
Steven Oday
1. A Phase II Trial of
AmplimexonTM (imexon,inj.) Plus Dacarbazine (DTIC) in
chemotherapy Naïve Patients with Unresectable Stage
III or Stage IV Malignant Melanoma
2. Randomized, Double-Blind, Placebo-Controlled Phase
II Study Comparing the Safety of MDX-010 Administered
with or Without Prophylactic Oral Budesonide (Entocort
EC) in Patients with Unresectable Stage III or IV Malignant
Melanoma
3. A Multi-Center, Single Arm Phase II Study of MDX-010
(BMS-734016) Monotherapy in Patients with Previously
Treated Unresectable Stage III or IV Melanoma
4. A Randomized, Double-Blind, Multi-Center, Phase
II Fixed Dose Study of Multiple Doses of Ipilimumab
(MDX-010) Monotherapy in Patients with Previously Treated
Unresectable Stage III or IV Melanoma
5. A Multi-Center, Open Label, Phase II Study of Ipilimumab
(MDX-010) Extended-Treatment Monotherapy or Follow Up
for Patients Previously Enrolled in Ipilimumab (MDX-010)
Protocols
6. A Phase II, Multi-Center, Blinded, Randomized, Controlled
Study of the Safety and Efficacy of the Human Monoclonal
Antibody to Humana? Integrins (CNTO95), alone and in
Combination with Dacarbazine, in Subjects with Stage
IV Melanoma
7. A Randomized, Double-Blind, Multicenter Study Comparing
MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma
Peptide Vaccine, and Melanoma Peptide Vaccine Monotherapy
in HLA-A*0201-Positive Patients with Previously Treated
Unresectable Stage III or IV Melanoma REGIMEN (double-blind):
MDX-010 alone,MDX-010+Vaccine, Vaccine alone
8.
Phase II Multicenter study of induction Biochemotherapy
concurrent Biochemotherapy followed by Prophylactic
Cranial Irradiation/ Temozolomide and Maintenance Biotherapy
in Responding Patients with Metastatic Melanoma
|
|
